NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,467 | -47.7% | 710 | +34.5% | 0.00% | -100.0% |
| Q2 2023 | $21,912 | -58.6% | 528 | -40.0% | 0.00% | 0.0% |
| Q1 2023 | $52,923 | -25.8% | 880 | -9.5% | 0.00% | -50.0% |
| Q4 2022 | $71,296 | -10.9% | 972 | -7.3% | 0.00% | -33.3% |
| Q3 2022 | $80,000 | -25.9% | 1,048 | -32.6% | 0.00% | -25.0% |
| Q2 2022 | $108,000 | -5.3% | 1,555 | +13.1% | 0.00% | +33.3% |
| Q1 2022 | $114,000 | +192.3% | 1,375 | +162.9% | 0.00% | +200.0% |
| Q4 2021 | $39,000 | +2.6% | 523 | +60.4% | 0.00% | 0.0% |
| Q3 2021 | $38,000 | -61.6% | 326 | -26.7% | 0.00% | -75.0% |
| Q2 2021 | $99,000 | +94.1% | 445 | +15.6% | 0.00% | +100.0% |
| Q1 2021 | $51,000 | -13.6% | 385 | +13.2% | 0.00% | -33.3% |
| Q4 2020 | $59,000 | +84.4% | 340 | +16.8% | 0.00% | +50.0% |
| Q3 2020 | $32,000 | +357.1% | 291 | +150.9% | 0.00% | – |
| Q2 2020 | $7,000 | -12.5% | 116 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $8,000 | +700.0% | 116 | +673.3% | 0.00% | – |
| Q4 2019 | $1,000 | – | 15 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |